Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced the presentation of data supporting the continued development of its lead therapeutic programs at United European Gastroenterology Week (UEGW), being held Oct. 8-11 in Vienna.
Related news for (SRZN)
- Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
- Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
- Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
- Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
- surrozen earns $10 million milestone payment in retinal diseases collaboration